Ahad Sadiq, MD
Hematology & Oncology · Fort Wayne, INNPI 1861525560
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $348,869 of the $430,482 with a category attached, or 81.0%. E.r. Squibb & Sons, L.L.C. accounts for 81.1% of it on its own, with 41 other manufacturers making up the rest. Reporting peaked in 2024 at $97,738 and has fallen 67.9% since, to $31,372 in 2025. Among hematology & oncology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 407 payments — averaging $1057.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$349K
- Merck$25K
- Boehringer Ingelheim$15K
- AstraZeneca$14K
- Takeda Pharmaceuticals U.S.A., Inc.$12K
- F. Hoffmann-la Roche AG$6K
- plus $10K from 36 others
Across 331 payments — averaging $10,676 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.3M
- AstraZeneca$525K
- Biontech SE$431K
- E.r. Squibb & Sons, L.L.C.$332K
- Genentech, Inc.$217K
- Daiichi Sankyo Inc.$142K
- plus $580K from 14 others
What the payments were for
- Consulting fees$41,27410%
- Speaking & faculty fees$348,86981%
- Travel & lodging$30,9447%
- Food & beverage$7,7132%
- Education$4850%
- Other$1,1980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$430,482 in reported general payments places this provider in the 95th percentile of 224 hematology & oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 32 | $613,542 |
| PromactaEltrombopag Olamine | 24 | $405,173 |
| TagrissoOsimertinib Mesylate | 14 | $242,338 |
| TalzennaTalazoparib Tosylate | 12 | $203,485 |
| EliquisApixaban | 82 | $70,269 |
| XareltoRivaroxaban | 50 | $51,351 |
| Abiraterone Acetate | 12 | $1,519 |
| Tamoxifen Citrate | 35 | $692 |
| Hydroxyurea | 35 | $582 |
| Dexamethasone | 32 | $560 |
| Acyclovir | 55 | $502 |
| Ondansetron OdtOndansetron | 31 | $452 |
| Anastrozole | 38 | $428 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 17 | $399 |
| Prochlorperazine Maleate | 39 | $380 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $31 | $613,54232 claims |
| NovartisPromacta | $1,388 | $405,17324 claims |
| PfizerTalzenna, Eliquis | $1,675 | $273,75594 claims |
| AstraZenecaTagrisso | $14,206 | $242,33814 claims |
| Johnson & JohnsonXarelto | $264 | $51,35150 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 224 hematology & oncology providers in Indiana.
Other hematology & oncology in Fort Wayne
- Zhentao ZhangFort Wayne$167K
- Sreenivasa NattamFort Wayne$120K
- Praveen KolliparaFort Wayne$88K
- Dolly Quispe LeveauFort Wayne$74K
- Matthew CarrFort Wayne$51K
- Shalini ChitneniFort Wayne$46K
- Ryan GonzalesFort Wayne$38K
- Robert MangesFort Wayne$31K
- Michael TooleFort Wayne$27K
- Melanie ClarkFort Wayne$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.